Current Hematologic Malignancy Reports

, Volume 2, Issue 2, pp 75–82

BCR-ABL-negative chronic myeloid leukemia

  • Sonja Burgstaller
  • Andreas Reiter
  • Nicholas C. P. Cross
Article

DOI: 10.1007/s11899-007-0011-5

Cite this article as:
Burgstaller, S., Reiter, A. & Cross, N.C.P. Curr Hematol Malig Rep (2007) 2: 75. doi:10.1007/s11899-007-0011-5

Abstract

Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous disease. Activated tyrosine kinases are excellent targets for signal transduction therapy, and an accurate diagnosis including morphology, karyotyping, and molecular genetics will become increasingly important to direct individualized treatment. In addition, new molecular findings need to be incorporated into disease classification systems.

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Sonja Burgstaller
  • Andreas Reiter
  • Nicholas C. P. Cross
    • 1
  1. 1.Wessex Regional Genetics LaboratoryUniversity of Southampton, Salisbury NHS Foundation TrustSalisburyUK

Personalised recommendations